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Hyperkalemia in acute glomerulonephritls due to transient hyporenin-
ernie hypoaldosteronism. Transient hyperkalemia has been reported to
occur in patients with acute glomerulonephritis, but the pathogenetic
mechanism has not been investigated systematically. We studied the
mechanism of hyperkalemia (5.7 to 6.7 mmollliter) in four men with
post-infectious glomerulonephritis. All four patients had clinical find-
ings consistent with acute glomerulonephritis (edema, hypertension,
proteinuria, hematuria, and an elevated ASO titer) and a renal biopsy
performed in three of the patients confirmed the diagnosis. In compar-
ison to normal subjects (N = 18), plasma aldosterone (5.4 1.6 vs. 22,8
2.6 ng/dl, P <0.005) and plasma renin activity (0.3 0.2 vs. 4.3 0.6
ng/ml/hr, P < 0.005) were reduced. Hyperkalemia resolved within one
to two weeks in two patients as the nephritis resolved and diuresis
ensued, and aldosterone and renin levels obtained at follow-up visits
were normal. Hyperkalemia persisted despite furosemide-induced di-
uresis in the other two patients, but resolved with fludrocortisone
treatment. Thus, hyperkalemia in patients with acute glomerulonephri-
tis is a manifestation, in part, of hyporeninemic hypoaldosteronism. It
is ameliorated by mineralocorticoid therapy and improves spontane-
ously with resolution of the glomerulonephritis.
Hyperkalemia due to impaired renal excretion of potassium
has been reported to occur transiently in patients with acute
glomerulonephritis [1], but the pathogenetic mechanism ac-
counting for this phenomenon has not been investigated sys-
tematically. Impaired renal excretion of potassium generally
results from severe renal insufficiency, decreased levels of or
tubular resistance to mineralocorticoid hormone, a primary
potassium secretory defect in the collecting tubule or a combi-
nation of these abnormalities [2]. Inasmuch as acute glomeru-
lonephritis is usually associated with only a moderate reduction
in glomerular function, renal insufficiency per se appears to be
an unlikely cause. In patients with mild to moderate renal
insufficiency, hyperkalemia is often due to hyporeninemic hy-
poaldosteronism, a syndrome recognized with increasing fre-
quency in the past two decades [3—7]. The purpose of the
present study was to evaluate the renin-aldosterone axis in
patients who developed hyperkalemia in the course of acute
post-infectious glomerulonephritis and to determine if the
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hyperkalemia could be ameliorated with diuretic [8] and/or
mineralocorticoid therapy [9].
Methods
Patients
Four men who developed hyperkalemia in association with
acute post-infectious glomerulonephritis were studied. Table 1
summarizes the clinical characteristics of the study group. All
patients had hypertension, edema, hematuna and proteinuria
and red blood cell casts were noted in two. Plasma volume was
increased in two of the three patients in whom this determina-
tion was made (normal range, 35 to 44 mI/kg body wt). The ASO
titer was elevated in all, and in the three patients in whom
complement levels were measured, serum C-3 was reduced. A
renal biopsy was performed in patients 2, 3 and 4 which
demonstrated findings confirming the diagnosis of acute prolif-
erative glomerulonephritis, including hypercellularity of the
glomeruli with a neutrophilic infiltrate, and intramembranous
and subepithelial deposits. Serum potassium concentration
ranged from 5.7 to 6.7 mmol/liter despite only a mild to
moderate reduction in the clearance of creatinine, which ranged
from 24 to 65 ml per minute (Table 1). Three of the four patients
has subnormal serum levels of total CO2 and hyperchloremia,
and arterial blood gases performed in patients 2 and 3 indicated
the presence of a mild metabolic acidosis. Plasma cortisol level
was normal (14.5, 9.7, and 9.4 jsg/dl) in the three patients (1, 2,
and 3) in whom the measurement was performed.
Plasma aldosterone levels and plasma renin activity (PRA)
were measured after the patients had been recumbent over-
night, and after two hours of upright activity. Urine aldosterone
excretion rates were also measured in patients 1, 2, and 3.
Dietary sodium intake for patients 1, 3 and 4 was 23, 99 and 87
mmol per day, respectively, and was ad libitum in patient 2.
Active clinical glomerulonephritis and the associated hyper-
kalemia resolved rapidly (within 1 to 2 weeks) in patients 1 and
2, whereas a protracted course of glomerulonephritis and per-
sistent hyperkalemia were observed in patients 3 and 4. Patient
3 was transferred to the General Clinical Research Center at
San Francisco General Hospital Medical Center where he was
placed on a constant metabolic diet containing 1.8 mmol
sodium, 1.0 mmol potassium and 40 kcal per kg body weight per
day. After four days of baseline observations, furosemide
treatment was begun, initially at a dose of 40mg per day for four
days and then at a dose of 80 mg per day for six additional days.
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Table 1. Clinical characteristics and laboratory data in patients with acute glomerulonephritis
Pt Age
BP
mm Hg Edema
Plasma
volume
mi/kg
RBC
casts
ASO
titer
Todd
units
C3
mg/di
Urine
protein
g/24 hr
Creatinine
clearance
mi/mm
Na K Cl TCO2 ArterialpH
mmoi/liter
1
2
3
4
34
47
46
17
166/108
135/90
158/103
170/100
+++
+++
++
++
61.6
ND
61.3
38.0
+
—
+
—
960
680
480
680
63
ND
49
74
3.1
7.5
6.1
15.5
65
39
24
35
137
137
128
142
6.7
6.0
5,7
6.4
109 19
112 18
105 13
107 28
ND
7.34
7.36
ND
ND = Not determined
Because of persistent hyperkalemia despite furosemide ther-
apy, fludrocortisone, 100 g per day, was added to the treat-
ment regimen and observations were continued for six addi-
tional days. Venous blood samples were obtained each morning
prior to breakfast and urine was collected in 24 hour pools for
measurement of sodium and potassium concentrations. In ad-
dition, blood was obtained after overnight recumbency and two
hours of upright activity every two to three days for measure-
ment of aldosterone and renin levels.
Patient 4 also failed to undergo a spontaneous diuresis during
nine days of observation. He was then treated sequentially with
furosemide (40 to 240 mg per day) and fludrocortisone (100
per day) for six and 18 days, respectively.
Laboratory methods
Sodium and potassium concentrations were measured using a
flame photometer. Serum and urine creatinine concentrations
were measured by enzymatic techniques on an automated
chemical analyzer. Plasma volume was determined by measur-
ing the volume of distribution of radiolabelled 1251 human serum
albumin and expressed as ml per kg ideal body weight. Plasma
renin activity [10] and plasma and urine aldosterone were
measured by radioimmunoassay [11].
Statistics
Data in the patients were compared to values in 18 normal
men ranging in age from 22 to 57 years old by one-way analysis
of variance and linear regression analysis as indicated. Differ-
ences were considered to be statistically significant at a P value
<0.05.
Results
Both plasma aldosterone levels and PRA were significantly
lower in the patients with acute glomerulonephritis than in the
control subjects (Table 2). Similarly, urine aldosterone excre-
tion was markedly reduced (2.0, 1.4, and 2.0 ttg/24 hr, normal 5
to 20 g/24 hr) in the three patients (1, 2, and 4) in whom it was
measured. We have reported previously that urinary aldoste-
rone excretion correlates positively with serum potassium
concentration in patients with hyporeninemic hypoaldosteron-
ism, albeit at a reduced level in comparison to subjects with
normal plasma renin levels [5]. As is evident in Figure 1, when
analyzed in this fashion, aldosterone excretion rates in the
patients with acute glomerulonephritis were significantly re-
duced in comparison to normal subjects and indistinguishable
from those with hyporeninemic hypoaldosteronism.
Plasma aldosterone and PRA were also measured in samples
obtained from patients 1 and 2 during the natriuretic/recovery
Table 2. Plasma aldosterone concentration and renin activity in
patients with acute glomerulonephritis
Pt
Plasma aldosterone
ng/di
Plasma renin activity
ng/mI/hr
Recumbent UprightRecumbent Upright
Patients with acute
glomerulonephritis
1 4.9 8.3 0.2 0.2
2 7.4 5.9 0.7 0.9
3 1.3 0.6 0.1 0.1
4 ND 6.6 ND 0.1
Mean 4.5' 54C 03b 0.3C
Normal control
subjects (N = 18)
Mean 8.9 22.8 1.8 4.3
Comparisons between the patient group and the normal control
subjects were made by one-way ANOVA. ND, Not determined.
a P < 0.03bP < 0.01
P <0.005
phase of their acute glomerulonephritis. In patient 2, attendant
with the diuresis (weight loss 2.5 kg), hyperkalemia was ame-
liorated (4.2 mmol/liter), and PRA (2.3 ng/ml/hr) and plasma
aldosterone concentration (11.8 ng/dl) returned to normal lev-
els. However, in patient 1, PRA (0.1 ng/ml/hr) and aldosterone
concentration (2.0 ng/dl) remained reduced despite a diuresis
(13.5 kg weight loss) and a return of plasma potassium concen-
tration to normal levels (4.2 mmol/liter). On a subsequent
outpatient follow-up visit three months later, patient 1 had a
normal PRA (1.2 ng/ml/hr).
In patient 3, hyperkalemia persisted despite treatment with
furosemide and a concomitant diuresis (4.4 kg weight loss).
Eventually a steady state ensued during which plasma potas-
sium averaged 5.7 mmol/liter and urinary sodium (136 5
mmolld) and potassium (33 I mmol/day) excretion were
constant (Fig. 2). Because of the failure of furosemide to
ameliorate hyperkalemia, fludrocortisone was added. Urinary
sodium excretion decreased and potassium excretion increased
resulting in positive sodium and negative potassium balance,
respectively. Plasma potassium concentration decreased rap-
idly in response to this therapy. Throughout both treatment
periods urinary aldosterone excretion and PRA levels remained
low. The patient was discharged from the hospital on fludro-
cortisone therapy and was subsequently lost to follow-up.
Patient 4 demonstrated a similar pattern in that his hyperkale-
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Fig. 1. Relationship between urinary aldosterone excretion and serum
potassium concentration in patients with acute glomerulonephritis (•),
hyporeninemic hypoaldosteronism (0). and normal control subjects(0). Urinary aldosterone excretion rates correlated positively with
plasma potassium concentration in the patients with HH (r = 0.58, P <
0.01) [5]. Urinary aldosterone excretion in three patients with acute >
glomerulonephritis was similar to that in the patients with HH.
mia (5.5 to 6.4 mmol/liter) was resistant to furosemide at a dose
of 240 mg/day despite a 3.1 kg weight loss, but was ameliorated
with 100 g of fludrocortisone (5.0 mmol/liter). Subsequently,
after his acute nephritis resolved, he was normokalemic (4.2
mmol/liter) and had a normal urinary aldosterone excretion rate
(30.3 gIday).
Discussion
The results of this study demonstrate that, in patients who
develop hyperkalemia during the course of acute post-infec-
tious glomerulonephritis, the renin-aldosterone axis is sup-
pressed. The magnitude of the reduction in aldosterone levels
observed in these patients is even more striking when consid-
ered in light of the markedly elevated levels of plasma potas-
sium, inasmuch as potassium directly stimulates aldosterone
biosynthesis [12, 13]. Aldosterone deficiency despite hyperkale-
mia could result from a primary abnormality in adrenocortical
function such as Addison's disease, which seems an unlikely
possibility in view of the normal levels of cortisol and the
absence of markedly elevated levels of PRA that are character-
istically seen in this disorder [14, 15]. Rather, aldosterone
deficiency despite hyperkalemia in these patients can be ac-
counted for by impaired renin secretion, in view of the evidence
that indicates a primary role of angiotensin II in the mainte-
nance of aldosterone biosynthesis [16, 171. The degree of
suppression of both aldosterone and renin noted in these
patients is comparable to that we [3, 5] and others [6, 7] have
reported to occur in patients with hyporeninemic hypoaldoste-
ronism. Yet, hyporeninemia hypoaldosteronism is usually seen
in the setting of chronic renal disease and tends to persist. To
our knowledge, acute glomerulonephritis is the only disorder in
which hyporeninemia and hypoaldosteronism are transient in
nature and are ameliorated with resolution of the nephritis.
As illustrated by patients 3 and 4, impaired renal potassium
excretion in patients with acute glomerulonephritis is mm-
eralocorticoid responsive. However, the observation that hy-
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Fig. 2 Plasma potassium concentration, urinary potassium, sodium
and aldosterone excretion, and plasma renin activity in response to
treatment with furosemide alone and in combination with fludrocorti-
sone in patient 3. Hyperkalemia persisted despite treatment with
furosemide at a dose of 80 mg per day. Eventually, a steady state
ensued during which the daily urinary potassium and sodium excretion
rates were constant (days I to 3). Values of A urine potassium and
sodium excretion represent the daily differences from the mean value
during these three days and those of I the accumulated sum of the
daily differences during the period of fludrocortisone treatment. In
response to fludrocortisone, urinary sodium excretion decreased and
potassium excretion increased resulting in positive sodium and negative
potassium balance, respectively. Plasma potassium decreased rapidly
in response to this therapy while plasma renin activity and urinary
aldosterone excretion rates remained low.
perkalemia was ameliorated during the recovery phase despite
persistent hypoaldosteronism (patient 1) indicates that factors
in addition to mineralocorticoid deficiency must be contributing
to the impaired renal potassium secretion that is present during
the acute nephritic phase. This is not surprising, inasmuch as
mineralocorticoid deficiency alone (such as, in patients with
Addison's disease who are maintained on glucocorticoid re-
placement therapy) does not ordinarily result in significant
hyperkalemia if renal function is normal, dietary sodium is
adequate, and potassium intake is not excessive [14]. A reduc-
tion in delivery of filtrate to the distal nephron consequent to
impaired glomerular filtration rate [18] might well be an addi-
tional factor that limits potassium secretion during the acute
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phase of glomerulonephritis, given the flow dependence of
potassium secretion in distal segments of the nephron [19].
Hyperkalemia has also been described in patients with sys-
temic lupus erythematosus in both the acute nephritic and
chronic stages of this disorder. The pathogenesis of this phe-
nomenon is unclear. On the basis of an impaired kaliUretic
response to sodium bicarbonate and mineralocorticoid therapy
in a single patient with acute lupus nephritis, Hadler, Gill and
Gardner [20] suggested that renal tubular potassium secretion is
impaired in this disorder. However, renin and aldosterone data
were not provided in that report. DeFronzo et al. [211 studied
two patients with lupus nephritis and noted that they had a
normal renin-aldosterone axis, but that the kaliuretic response
to treatment with mineralocorticoid or acetazolamide plus
bicarbonate was impaired. They also concluded that these
patients had a primary defect in renal tubular potassium secre-
tion. In contrast to these findings, Lee et al [22] screened a large
population of patients with systemic lupus erythematosus and
noted that those with hyperkalemia had reduced levels of PRA
and plasma aldosterone which failed to respond appropriately
to either furosemide or captopril stimulation. They concluded
that hyporeninemic hypoaldosteronism plays an important role
in the pathogenesis of hyperkalemia in systemic lupus erythe-
matosus.
It is possible that, in addition to impaired aldosterone secre-
tion, patients with hyperkalemic post-infectious glomerulone-
phritis may have a component of tubular unresponsiveness to
mineralocorticoid hormone to account for the hyperkalemia.
Often with acute glomerulonephntis, there is an associated
interstitial nephritis [23] and this may impair distal tubular
function. Rubini, Sanford and Meroney [24], in a report of a
patient with acute post-infectious glomerulonephritis, attrib-
uted the hyperkalemia to a primary potassium secretory defect
because the patient's aldosterone excretion rates were normal
or increased. However, the patient did have an appropriate
kaliuresis after treatment with sodium bicarbonate or acetazol-
amide. Thus, it seems unlikely that this patient had a true
primary tubular defect resulting in impaired secretion of potas-
sium, but rather tubular resistance to mineralocorticoid hor-
mone.
The pathogenesis of hyporeninemia in acute glomerulone-
phritis is unknown. Both damage to the juxtaglomerular appa-
ratus with impaired release of renin as well as physiologic
suppression of renin secretion by volume expansion, which
have been proposed as possible pathogenetic factors in patients
with chronic renal diseases and hyporeninemic hypoaldoste-
ronism [4, 25, 261, may be operative in acute glomerulone-
phritis. Artenolitis can occur in acute glomerulonephritis [27]
so that an inflammatory process affecting juxtaglomerular ap-
paratus might impair renin release. Glassock et al [1] have
proposed that PR.A is suppressed in patients with acute glomer-
ulonephritis as a consequence of volume expansion [28, 29]
resulting from the primary renal sodium and water retention
characteristic of this disorder [18]. Intravascular volume expan-
sion was present in two of the three patients in whom plasma
volume determinations were obtained. In addition to volume
medicated suppression of renin secretion, were the primary
renal sodium reabsorption to occur in the macula densa seg-
ment of the nephron, the secretion of remn might be suppressed
by a non-baroreceptor mechanism [30].
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